Radius Health Inc
NASDAQ:RDUS

Watchlist Manager
Radius Health Inc Logo
Radius Health Inc
NASDAQ:RDUS
Watchlist
Price: 30 USD Market Closed
Market Cap: 847.8m USD

Operating Margin
Radius Health Inc

-2.2%
Current
1%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2.2%
=
Operating Profit
-60.8m
/
Revenue
2.8B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Radius Health Inc
NASDAQ:RDUS
847.7m USD
-2%
IL
Can Fite Biopharma Ltd
TASE:CANF
168.5T ILS
-1 487%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
382.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
175.6B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
153.4B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
28%
AU
CSL Ltd
ASX:CSL
84.9B AUD
26%
NL
argenx SE
XBRU:ARGX
42.8B EUR
22%
No Stocks Found

Radius Health Inc
Glance View

Market Cap
847.7m USD
Industry
Biotechnology

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company is headquartered in Boston, Massachusetts and currently employs 293 full-time employees. The company went IPO on 2014-06-06. The firm is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The firm also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

RDUS Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2.2%
=
Operating Profit
-60.8m
/
Revenue
2.8B
What is the Operating Margin of Radius Health Inc?

Based on Radius Health Inc's most recent financial statements, the company has Operating Margin of -2.2%.

Back to Top